JP7846613B2 - 病原菌を抑制するための組成物及び方法 - Google Patents

病原菌を抑制するための組成物及び方法

Info

Publication number
JP7846613B2
JP7846613B2 JP2022508590A JP2022508590A JP7846613B2 JP 7846613 B2 JP7846613 B2 JP 7846613B2 JP 2022508590 A JP2022508590 A JP 2022508590A JP 2022508590 A JP2022508590 A JP 2022508590A JP 7846613 B2 JP7846613 B2 JP 7846613B2
Authority
JP
Japan
Prior art keywords
bacteroides
sequence
clostridium
nucleic acid
bacterial strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022508590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544380A5 (https=
JP2022544380A (ja
Inventor
カバレロ，シルヴィア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vedanta Biosciences Inc
Original Assignee
Vedanta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vedanta Biosciences Inc filed Critical Vedanta Biosciences Inc
Publication of JP2022544380A publication Critical patent/JP2022544380A/ja
Publication of JP2022544380A5 publication Critical patent/JP2022544380A5/ja
Application granted granted Critical
Publication of JP7846613B2 publication Critical patent/JP7846613B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022508590A 2019-08-09 2020-08-07 病原菌を抑制するための組成物及び方法 Active JP7846613B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962884917P 2019-08-09 2019-08-09
US62/884,917 2019-08-09
US201962901206P 2019-09-16 2019-09-16
US62/901,206 2019-09-16
US201962947517P 2019-12-12 2019-12-12
US62/947,517 2019-12-12
US202063031299P 2020-05-28 2020-05-28
US63/031,299 2020-05-28
PCT/US2020/045442 WO2021030198A1 (en) 2019-08-09 2020-08-07 Compositions and methods for suppressing pathogenic organisms

Publications (3)

Publication Number Publication Date
JP2022544380A JP2022544380A (ja) 2022-10-18
JP2022544380A5 JP2022544380A5 (https=) 2023-08-17
JP7846613B2 true JP7846613B2 (ja) 2026-04-15

Family

ID=74571198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508590A Active JP7846613B2 (ja) 2019-08-09 2020-08-07 病原菌を抑制するための組成物及び方法

Country Status (5)

Country Link
US (1) US20220409674A1 (https=)
EP (1) EP4010013A4 (https=)
JP (1) JP7846613B2 (https=)
CN (1) CN114502183A (https=)
WO (1) WO2021030198A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3706767A4 (en) * 2017-11-09 2021-12-15 Vedanta Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF AN ALLERGY
EP3723776A4 (en) 2017-12-11 2022-07-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
GB202217266D0 (en) * 2022-11-18 2023-01-04 Imperial College Innovations Ltd Anti-biotic-resistant bacteria
EP4687930A2 (en) * 2023-01-30 2026-02-11 Seres Therapeutics, Inc. Use of designed bacterial compositions for infection treatment
EP4687931A1 (en) * 2023-04-04 2026-02-11 Vedanta Biosciences, Inc. Compositions and methods for treating or preventing clostridium difficile infection, neutropenia, cardiovascular disease, asthma, and/or cancer
WO2025166242A1 (en) * 2024-02-01 2025-08-07 Vedanta Biosciences, Inc. Compositions and methods for decreasing dysbiosis and/or preventing inflammatory bowel disease
EP4663196A1 (en) 2024-06-13 2025-12-17 Helmholtz-Zentrum für Infektionsforschung GmbH Decolonization of pathogenic enterobacteria, such as e. coli and/or klebsiella pneumoniae, from the gut using strains of e. coli

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118515A2 (en) 2017-12-11 2019-06-20 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2007075186A2 (en) * 2005-04-18 2007-07-05 The Regents Of The University Of California Antimicrobial therapy for bacterial infections
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10973861B2 (en) * 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
EP2994758B1 (en) * 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US9999641B2 (en) * 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20180000872A1 (en) * 2016-07-01 2018-01-04 Regents Of The University Of Minnesota Compositions and methods for c. difficile treatment
WO2018023003A1 (en) * 2016-07-29 2018-02-01 Isothrive Llc Optimized individualized prebiotic compositions
AU2017318650B2 (en) * 2016-09-02 2021-12-09 Société des Produits Nestlé S.A. Compositions and methods for modulating gastrointestinal microflora in a canine
WO2018136884A1 (en) * 2017-01-23 2018-07-26 The Regents Of The University Of California Compositions and methods for treating obesity and inducing weight loss
AU2018302641B2 (en) * 2017-07-18 2024-12-19 Keio University Anti-bacterial composition against Th1 cell-inducing bacteria
CN117202919A (zh) * 2021-02-18 2023-12-08 韦丹塔生物科学股份有限公司 用于抑制病原生物体的组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118515A2 (en) 2017-12-11 2019-06-20 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms

Also Published As

Publication number Publication date
EP4010013A1 (en) 2022-06-15
US20220409674A1 (en) 2022-12-29
EP4010013A4 (en) 2023-12-06
CN114502183A (zh) 2022-05-13
WO2021030198A1 (en) 2021-02-18
JP2022544380A (ja) 2022-10-18

Similar Documents

Publication Publication Date Title
JP7846613B2 (ja) 病原菌を抑制するための組成物及び方法
US12390498B2 (en) Treatment of clostridium difficile infection
US20250009811A1 (en) Compositions and methods for suppressing pathogenic organisms
US11701396B2 (en) Treatment of Clostridium difficile infection
US20240316119A1 (en) Compositions and methods for suppressing pathogenic organisms
EP4704871A2 (en) Compositions and methods for treating clostridioides difficile infection
HK40104391A (en) Treatment of clostridium difficile infection
HK40114606A (en) Compositions and methods for suppressing pathogenic organisms
HK40007703A (en) Treatment of clostridium difficile infection
HK40007703B (en) Treatment of clostridium difficile infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260403

R150 Certificate of patent or registration of utility model

Ref document number: 7846613

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150